Elevated Serum Uric Acid is Associated With Poor Survival in Advanced HCC Patients and Febuxostat Improves Prognosis in HCC Rats
Objective: Serum uric acid is associated with tumor progression and hepatocarcinogenesis. Here, we aimed to determine whether serum uric acid is related to the survival time of patients with hepatocellular carcinoma (HCC) and whether the inhibition of uric acid production affects the progression and...
Guardado en:
Autores principales: | Le Wu, Wenlong Yang, Yu Zhang, Xiaoyue Du, Nan Jin, Wen Chen, Huangbao Li, Shouhua Zhang, Baogang Xie |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a72d3781a7747928e156a18442e59f6 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Efficacy and safety of febuxostat in elderly female patients
por: Mizuno T, et al.
Publicado: (2014) -
Management of hyperuricemia in gout: focus on febuxostat
por: Mattheus K Reinders, et al.
Publicado: (2010) -
Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion
por: Chunye Zhang, et al.
Publicado: (2021) -
Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC
por: Paola Dongiovanni, et al.
Publicado: (2021) -
Targeting Immune Cells in the Tumor Microenvironment of HCC: New Opportunities and Challenges
por: Xiaopei Hao, et al.
Publicado: (2021)